Company news
Percheron Therapeutics Limited news in 2023
Percheron Therapeutics Limited's news releases, calls and decks from 2023, newest first.
Positive Data for ATL1102 in Limb Girdle Muscular Dystrophy
September 25, 2023
Antisense Share Purchase Plan (SPP) Raises $3.26 Million
August 20, 2023
Share Purchase Plan (SPP) Offer Booklet
July 28, 2023
Positive new DMD Combination Therapy Data in mdx mice
July 25, 2023
Intention to launch Share Purchase Plan
July 20, 2023
Quarterly Activities Report
July 20, 2023
Institutional Placement and proposed Share Purchase Plan SPP
July 18, 2023
MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK
June 27, 2023
First Patient Dosed in ATL1102 Phase IIb DMD Trial
June 7, 2023
Chief Executive Officer and Managing Director Appointment
May 7, 2023
PIIb DMD trial approved in Bulgaria- UK, Australia advancing
April 26, 2023
Dosing commenced in the ATL1102 toxicology study
March 13, 2023
Receipt of R&D Tax Incentive Payment
February 22, 2023
First approval for ATL1102 Phase IIb DMD clinical trial
February 13, 2023
Limb Girdle Muscular Dystrophy R2 animal study commenced
February 12, 2023
Positive outcomes in DMD combination therapy animal study
January 31, 2023